talotrexin has been researched along with Benign Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frühauf, J; Gangjee, A; Hou, Z; Matherly, LH; Ning, C; O'Connor, C; Tong, N; Wallace-Povirk, A | 1 |
| Veryard, C | 1 |
2 other study(ies) available for talotrexin and Benign Neoplasms
| Article | Year |
|---|---|
Folate transporter dynamics and therapy with classic and tumor-targeted antifolates.
Topics: Biological Transport; Cell Proliferation; Folate Receptor 1; Folic Acid; Folic Acid Antagonists; HeLa Cells; Humans; Methotrexate; Neoplasms; Ornithine; Pemetrexed; Proton-Coupled Folate Transporter; Pterins; Reduced Folate Carrier Protein | 2021 |
AACR-NCI-EORTC--17th symposium: Molecular targets and cancer therapeutics. 14-18th November 2005, Philadelphia, PA, USA.
Topics: Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodiazepinones; Clinical Trials, Phase I as Topic; ErbB Receptors; Humans; Neoplasms; Ornithine; Pterins; Pyrroles; Receptor, EphA2; Societies, Scientific | 2006 |